Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent ...
The company has multiple drugs in its pipeline that could generate billions in revenue.
Investor's Business Daily on MSN
Why Erasca, up 415% this year amid revolution-tied furor, just lost half its value
Erasca stock crashed Tuesday after a patient in its pancreatic cancer study died following a bout of pneumonia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results